Peter DorfmÃ¼ller

List of Publications by Year
in descending order

60 papers	6,971 citations	94415 37 h-index	138468 58 g-index
61 all docs	61 docs citations	61 times ranked	6320 citing authors

#	Article	IF	Citations
1	Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. European Respiratory Journal, 2019, 53, 1801887.	6.7	776
2	Relevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D4-D12.	2.8	465
3	Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension. Circulation, 2015, 131, 1006-1018.	1.6	441
4	Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 81-88.	5.6	405
5	EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nature Genetics, 2014, 46, 65-69.	21.4	351
6	Pulmonary Veno-Occlusive Disease. Medicine (United States), 2008, 87, 220-233.	1.0	295
7	Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Human Pathology, 2007, 38, 893-902.	2.0	291
8	Pulmonary veno-occlusive disease. European Respiratory Journal, 2016, 47, 1518-1534.	6.7	289
9	ERS statement on chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002828.	6.7	287
10	Pulmonary Lymphoid Neogenesis in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 311-321.	5.6	249
11	Pulmonary arterial hypertension. Orphanet Journal of Rare Diseases, 2013, 8, 97.	2.7	226
12	Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. European Respiratory Journal, 2014, 44, 1275-1288.	6.7	201
13	Increased Pericyte Coverage Mediated by Endothelial-Derived Fibroblast Growth Factor-2 and Interleukin-6 Is a Source of Smooth Muscleâ€“Like Cells in Pulmonary Hypertension. Circulation, 2014, 129, 1586-1597.	1.6	178
14	Chemotherapy-Induced Pulmonary Hypertension. American Journal of Pathology, 2015, 185, 356-371.	3.8	149
15	Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 983-997.	5.6	144
16	Immune Dysregulation and Endothelial Dysfunction in Pulmonary Arterial Hypertension. Circulation, 2014, 129, 1332-1340.	1.6	141
17	Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1371-1385.	1.6	141
18	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases. European Respiratory Journal, 2018, 51, 1700745.	6.7	136

#	Article	IF	Citations
19	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respiratory Medicine,the, 2017, 5, 125-134.	10.7	123
20	The Pathobiology of Chronic Thromboembolic Pulmonary Hypertension. Annals of the American Thoracic Society, 2016, 13, S215-S221.	3.2	121
21	Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation, 2017, 136, 2022-2033.	1.6	111
22	Mitomycin-Induced Pulmonary Veno-Occlusive Disease. Circulation, 2015, 132, 834-847.	1.6	103
23	Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension. Circulation, 2013, 128, 512-523.	1.6	97
24	Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1273-1285.	5.6	88
25	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further researchâ€. European Heart Journal, 2017, 38, ehw597.	2.2	83
26	Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. Journal of Clinical Investigation, 2011, 121, 2888-2897.	8.2	83
27	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. European Respiratory Journal, 2015, 46, 1721-1731.	6.7	80
28	Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1747-1760.	1.6	75
29	BMPR2mutation status influences bronchial vascular changes in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1668-1681.	6.7	68
30	Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. Respiratory Research, 2011, 12, 119.	3.6	67
31	Cytotoxic Cells and Granulysin in Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 189-196.	5.6	54
32	Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation. Circulation, 2019, 140, 1409-1425.	1.6	54
33	Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 148-157.	5.6	53
34	Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. Cardiovascular Research, 2018, 114, 880-893.	3.8	52
35	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. Journal of Heart and Lung Transplantation, 2018, 37, 647-655.	0.6	50
36	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. Nature Reviews Cardiology, 2022, 19, 314-331.	13.7	46

#	Article	IF	Citations
37	Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. European Respiratory Journal, 2014, 44, 1069-1072.	6.7	43
38	Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension. Circulation, 2021, 144, 52-73.	1.6	38
39	Pulmonary Arterial Histologic Lesions in Patients With COPD With Severe Pulmonary Hypertension. Chest, 2019, 156, 33-44.	0.8	37
40	Resident PW1 ⁺ Progenitor Cells Participate in Vascular Remodeling During Pulmonary Arterial Hypertension. Circulation Research, 2016, 118, 822-833.	4.5	34
41	Inhibition of B cellâ€“dependent lymphoid follicle formation prevents lymphocytic bronchiolitis after lung transplantation. JCI Insight, 2019, 4, .	5.0	28
42	Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 118-131.	2.9	24
43	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. Nature Metabolism, 2020, 2, 532-546.	11.9	23
44	Right ventricular plasticity in a porcine model of chronic pressure overload. Journal of Heart and Lung Transplantation, 2014, 33, 194-202.	0.6	20
45	Group 3 Pulmonary Hypertension: From Bench to Bedside. Circulation Research, 2022, 130, 1404-1422.	4.5	19
46	Pulmonary vascular disease and pulmonary hypertension. Diagnostic Histopathology, 2019, 25, 304-312.	0.4	18
47	Pulmonary capillary haemangiomatosis: a distinct entity?. European Respiratory Review, 2020, 29, 190168.	7.1	17
48	Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology. Annals of Cardiothoracic Surgery, 2022, 11, 106-119.	1.7	17
49	The importance of capillary densityâ€“stroke work mismatch for right ventricular adaptation to chronic pressure overload. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 2070-2079.	0.8	15
50	Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet. Journal of Visualized Experiments, 2015, , e53133.	0.3	13
51	Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 537-541.	5.6	12
52	Interplay of sex hormones and long-term right ventricular adaptation in a Dutch PAH-cohort. Journal of Heart and Lung Transplantation, 2022, 41, 445-457.	0.6	12
53	Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2021, 22, 9105.	4.1	10
54	Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension. European Respiratory Review, 2021, 30, 210161.	7.1	5

#	Article	IF	Citations
55	Response to Letter Regarding Article, â€œMitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Modelâ€. Circulation, 2016, 133, e592-3.	1.6	4
56	Trichloroethylene increases pulmonary endothelial permeability: implication for pulmonary venoâ€•occlusive disease. Pulmonary Circulation, 2020, 10, 1-4.	1.7	4
57	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. Journal of Clinical Immunology, 2021, 41, 1549-1562.	3.8	3
58	Capillary density in right ventricular myocardium in congenital heart disease. Journal of Heart and Lung Transplantation, 2019, 38, 328-331.	0.6	1
59	Inflammation in Pulmonary Arterial Hypertension. , 2012, , 213-229.		1
60	Pulmonary veno-occlusive disease associated with long-term occupational exposure to chemical solvents and pesticides. A case report. Respiratory Medicine and Research, 2022, , 100943.	0.6	0